Meagan20230905v2 - Four Icons
Gaining a better understanding of infectious diseases, including their characterization, evolution and transmission, continues to be a priority, both from an R&D standpoint and as a public health issue. The COVID-19 pandemic has demonstrated the need for a wide range of tools to research infectious diseases, develop diagnostics and vaccines, and conduct epidemiological and surveillance studies. It has also highlighted the importance of speed and the ability to pivot as new problems arise. This has emphasized the need for innovation and thinking differently about where to access critical materials, including genomics reagents.
Many scientists know NEB as a trusted reagent supplier to the life science community, having had formative lab experience with our reagents and tools. What you may not know is that we also offer a portfolio of products that can be used in infectious disease research, development of diagnostics and therapies, as well as in epidemiological studies and disease surveillance. Many of our products have played a role in the global response to SARS-CoV-2, from supporting the development of COVID-19 diagnostics and vaccines to improving the speed and accuracy of Illumina® and Nanopore-based COVID-19 sample analysis. They can also be utilized with other infectious diseases, such as influenza and malaria, in multiplex assays for simultaneous detection and differentiation. Most recently, we designed a multiplex assay to detect monkeypox virus DNA using Luna® qPCR reagents.